pSivida Corp. (PSDV)
-NasdaqGM 2.83 
0.04(1.43%) May 17, 4:00PM EDT
| Prev Close: | 2.79 |
|---|
| Open: | 2.83 |
|---|
| Bid: | 1.34 x 300 |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 4.00 |
|---|
| Beta: | 1.79 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 2.80 - 2.88 |
|---|
| 52wk Range: | 1.17 - 3.50 |
|---|
| Volume: | 87,191 |
|---|
| Avg Vol (3m): | 143,587 |
|---|
| Market Cap: | 65.93M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.46 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- PSIVIDA CORP. Files SEC form 10-Q, Quarterly ReportEDGAR Online(Tue, May 14)
- pSivida Corp's CEO Discusses Q3 2013 Results - Earnings Call Transcriptat Seeking Alpha(Mon, May 13)
- pSivida Corp. Reports Third Quarter Fiscal Year 2013 ResultsBusiness Wire(Mon, May 13)
- PSIVIDA CORP. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and ExhibitsEDGAR Online(Mon, May 13)
- Q3 2013 pSivida Corp. Earnings Release - After Market CloseCCBN(Mon, May 13)
- Alimera Sciences And Trius Therapeutics: 2 Big Biotechs For 2013at Seeking Alpha(Mon, May 13)
- pSivida Corp. Announces Commercial Launch of ILUVIEN® in Germany with First Patient TreatedBusiness Wire(Tue, May 7)
- pSivida Corp. Announces Third Quarter 2013 Financial Results Release Date and Conference Call InformationBusiness Wire(Mon, May 6)
- Ophthalmology: A Niche Where Innovation Paysat Seeking Alpha(Mon, May 6)
- 5 Stocks Under $10 Set to Surgeat TheStreet(Thu, May 2)
- pSivida Corp. Announces New ILUVIEN® PDUFA Date of October 17, 2013Business Wire(Wed, May 1)
- pSivida Reports ILUVIEN® Available in UKBusiness Wire(Mon, Apr 29)
- For Iluvien, The FDA Isn't The Issue; European Sales Areat Seeking Alpha(Wed, Apr 24)
- pSivida Corp. President and CEO, Dr. Paul Ashton Publishes Blog Post Titled ''Transformational Change and Ophthalmology''Accesswire(Wed, Apr 17)
- IBM is a Buy and 3 More Analyst Upgrades to Know Nowat Wall St. Cheat Sheet(Wed, Apr 10)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 27.66 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Jun-13)
: | -0.47 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.12 |
|---|
| Mean Recommendation*: | 1.0 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
pSivida Corp., together with its subsidiaries, develops drug delivery products for treatment of back-of-the-eye diseases that are administered by implantation, injection, or insertion.
View More